 |
市場調查報告書
商品編碼
1629602
血鐵沉著症症市場按類型、診斷方法（血液檢測、影像技術）、治療類型、年齡層、最終用戶和地區分類Hemochromatosis Market, By Type, By Diagnosis Method (Blood Tests, Imaging Techniques, By Treatment Type, By Age Group, By End User, By Geography |
||||||
2024 年全球血鐵沉著症市場規模估計為 16 億美元，預計 2031 年將達到 24.1 億美元，2024 年至 2031 年的複合年成長率為 6%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2023 | 2024 年的市場規模 | 16億美元 |
| 效能資料 | 2019 年至 2023 年 | 預測期 | 2024 年至 2031 年 |
| 預測期間 2024 年至 2031 年複合年成長率： | 6.00％ | 2031 年價值預測 | 24.1億美元 |
有幾個因素推動了對血鐵沉著症治療和管理的需求，包括遺傳性血鐵沉著症盛行率的增加和對鐵超載的認知的提高。
市場動態：
全球血鐵沉著症市場的成長主要受到全球遺傳性血鐵沉著症盛行率上升的推動。 Medscape 估計，到 2023 年 6 月，大約有 100 萬美國人將患有遺傳性血鐵沉著症並且未被診斷。提高對鐵過載早期診斷和治療的認知將對市場成長產生積極影響。此外，擴大採用篩檢計劃來早期發現血鐵沉著症，進一步推動了市場的成長。然而，進行基因測試和肝臟切片檢查的高成本可能會在一定程度上阻礙市場的成長。然而，對先進診斷方法的開發和基因檢測的採用的持續研究預計將在預測期內為市場參與者創造有利可圖的機會。
本研究的主要特點
本報告對全球血鐵沉著症市場進行了詳細分析，並提供了預測期（2024-2031 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設基準年為 2023 年。
它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球血鐵沉著症市場的主要企業。
本研究涉及的主要企業包括諾華公司、賽諾菲公司、安進公司、武田製藥有限公司、輝瑞公司、Ironwood Pharmaceuticals, Inc.、Celgene Corporation、基因泰克公司、第一三共株式會社、Teva Pharmaceutical Industries Ltd.、HemoShear Therapeutics, LLC、Erytech Pharmar、Allam
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過全球血鐵沉著症市場分析中使用的各種策略矩陣來促進他們的決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要進展
- 監管情景
- 產品發布/核准
- PEST分析
- PORTER 分析
- 併購情景
- 產業趨勢
4. 2019 年至 2031 年全球血鐵沉著症市場（按類型）
- 原發性血鐵沉著症（遺傳性）
- 次發性血鐵沉著症症（後天）
5. 全球血鐵沉著症市場，依診斷方法，2019 年至 2031 年
- 血液檢查
- 血清鐵蛋白
- 轉鐵蛋白飽和度
- 成像技術
- 磁振造影（MRI）
- 電腦斷層掃描 (CT)
- 切片檢查
- 基因檢測
6. 2019 年至 2031 年全球血鐵沉著症市場（依治療類型）
- 放血
- 螯合療法
- 飲食管理
- 其他
7. 2019 年至 2031 年按年齡層別分類的全球血鐵沉著症市場
- 孩子們
- 成人
- 老年人
8. 全球血鐵沉著症市場，依最終用戶分類，2019 年至 2031 年
- 醫院
- 診斷實驗室
- 手術中心
- 家庭護理設置
9. 2019 年至 2031 年全球血鐵沉著症市場（按地區分類）
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第10章 競爭格局
- Novartis AG
- Sanofi SA
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Ironwood Pharmaceuticals, Inc.
- Celgene Corporation
- Genentech, Inc.
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- HemoShear Therapeutics, LLC
- Erytech Pharma SA
- Alnylam Pharmaceuticals, Inc.
- HemaCare Corporation
- Invitae Corp.
第 11 章 分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第 12 章參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
The global hemochromatosis market is estimated to be valued at USD 1.60 Bn in 2024 and is expected to reach USD 2.41 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 1.60 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 6.00% | 2031 Value Projection: | US$ 2.41 Bn |
Several factors such as increasing prevalence of hereditary hemochromatosis and rising awareness regarding iron overload disorders are driving the demand for hemochromatosis treatment and management.
Market Dynamics:
The global hemochromatosis market growth is primarily driven by the rising prevalence of hereditary hemochromatosis across the globe. As per estimates from Medscape, in June 2023, around 1 million Americans suffer from hereditary hemochromatosis which remains undiagnosed. Increasing awareness about the early diagnosis and treatment of iron overload disorders is positively impacting the market growth. Moreover, increasing adoption of screening programs for the early detection of hemochromatosis is further fueling the market growth. However, high costs associated with genetic testing and liver biopsy procedures may hinder the market growth to some extent. Nevertheless, ongoing research for the development of advanced diagnostics and introduction of genetic testing are expected to create lucrative opportunities for market players over the forecast period.
Key Features of the Study:
This report provides in-depth analysis of the global hemochromatosis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemochromatosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study Novartis AG, Sanofi S.A., Amgen Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Ironwood Pharmaceuticals, Inc., Celgene Corporation, Genentech, Inc., Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., HemoShear Therapeutics, LLC, Erytech Pharma S.A., Alnylam Pharmaceuticals, Inc., HemaCare Corporation, and Invitae Corp.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global hemochromatosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemochromatosis market.
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2019 - 2031)
- Primary Hemochromatosis (Hereditary)
- Secondary Hemochromatosis (Acquired)
- By Diagnosis Method Insights (Revenue, USD Bn, 2019 - 2031)
- Blood Tests
- Serum Ferritin
- Transferrin Saturation
- Imaging Techniques
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT) scans
- Liver Biopsy
- Genetic Testing
- By Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
- Phlebotomy
- Chelation Therapy
- Dietary Management
- Others
- By Age Group Insights (Revenue, USD Bn, 2019 - 2031)
- Pediatric
- Adult
- Geriatric
- By End User Insights (Revenue, USD Bn, 2019 - 2031)
- Hospitals
- Diagnostic Laboratories
- Surgical Centers
- Home Care Settings
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Sanofi S.A.
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Ironwood Pharmaceuticals, Inc.
- Celgene Corporation
- Genentech, Inc.
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- HemoShear Therapeutics, LLC
- Erytech Pharma S.A.
- Alnylam Pharmaceuticals, Inc.
- HemaCare Corporation
- Invitae Corp.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Hemochromatosis Market, By Type
- Global Hemochromatosis Market, By Diagnosis Method
- Global Hemochromatosis Market, By Treatment Type
- Global Hemochromatosis Market, By Age Group
- Global Hemochromatosis Market, By End User
- Global Hemochromatosis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Hemochromatosis Market, By Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Primary Hemochromatosis (Hereditary)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Secondary Hemochromatosis (Acquired)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Global Hemochromatosis Market, By Diagnosis Method, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Blood Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Serum Ferritin
- Transferrin Saturation
- Imaging Techniques
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT) scans
- Liver Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Genetic Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Hemochromatosis Market, By Treatment Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Phlebotomy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Chelation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Dietary Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Hemochromatosis Market, By Age Group, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Hemochromatosis Market, By End User, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
9. Global Hemochromatosis Market, By Region, 2019 - 2031, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Ironwood Pharmaceuticals, Inc.
- Celgene Corporation
- Genentech, Inc.
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- HemoShear Therapeutics, LLC
- Erytech Pharma S.A.
- Alnylam Pharmaceuticals, Inc.
- HemaCare Corporation
- Invitae Corp.
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
